PR Newswire LAS VEGAS, June 10, 2025 The growth hormone deficiency market is expected to see expansion across the 7MM driven by the introduction of innovative therapies, including ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) (佳泰莱 ®) in combination with ...